have a question, issue or just some feedback for us? we're here for you.

what can we help you with?

let us know how we can help

DISCLAIMER

The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.

compose your message

to*

from*

subject

message

message sent

email sent successfully

suggest a poll

you must have an account to suggest polls.

join now

You are receiving this because you have an account on www.oneGRAVESvoice.com
To unsubscribe from these emails, click here

Trusted Resources: News & Meetings

Latest announcements and gatherings

Clinical Trials And Research
Business
People
Spotlight
Happenings
Fundraising Events

Back to News & Meetings / Clinical Trials And Research

Tepezza Treatment Correlates to Improved Extraocular Muscle Size, Clinical Outcomes

Patients who received Tepezza to treat thyroid eye disease showed improved extraocular muscle size that correlated to improved diplopia and motility, according to a presenter here. “Thyroid eye disease is known to cause inflammation, expansion and fibrosis of extraocular muscles and connective tissue of the orbit. The mechanism involves upregulation of TSHR and IGF-1R complex in orbital fibroblasts,” Edith R. Reshef, MD, of Massachusetts Eye and Ear, said at the ASOPRS Fall Scientific Symposium.

“Teprotumumab inhibits this pathway, thereby decreasing inflammatory response. The purpose of this study was to assess and quantify changes in extraocular muscle size as measured by cross-sectional area on CT in TED following teprotumumab therapy. We also sought to assess correlation between changes in extraocular muscle size and clinical outcomes of teprotumumab therapy.”

Source: https://www.healio.com/news/ophthalmology/20221006/tepezza-treatment-correlates-to-improved-extraocular-muscle-size-clinical-outcomes

Discuss in Social Wall

Twitter

Share to rareTeam

myBinder

send a message

send to:
subject:
message:

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Trusted Resources Home

Evidence & Education

People & Places

News & Meetings

Videos & Visuals

Partner Pages

Tepezza Treatment Correlates to Improved Extraocular Muscle Size, Clinical Outcomes

Related Content

Powered by

Trusted Resources Home

Evidence & Education

People & Places

Community Center

News & Meetings

Videos & Visuals

Partner Pages

Trusted Resources: News & Meetings

Latest announcements and gatherings

Tepezza Treatment Correlates to Improved Extraocular Muscle Size, Clinical Outcomes

Related Content

Powered by